CoChat

Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine.

Frances, B, Gout, R, Monsarrat, B, Cros, J, Zajac, J M · 1992 · The Journal of Pharmacology and Experimental Therapeutics
Cited by 163

The DOI matches its Crossref record.

Abstract

The antinociceptive properties of morphine-6 beta-glucuronide (M6G) and morphine (oral, i.c.v. and s.c.) were examined in two tests involving different nociceptive stimuli [i.e., cutaneous-thermal (tail-flick) and chemical-visceral (acetic acid-writhing)] in both naive and chronically treated mice. Twenty min after i.c.v. injection, M6G was 47 and 360 times more potent than morphine in the writhing and tail-flick tests, respectively. This difference was not due to differences in affinity because M6G displayed lower apparent affinities (Ki) for mu and kappa binding sites in vitro. After systemic injection, the two opiates were equieffective, although M6G produced a 10-fold longer antinociceptive effect. These differences with route of administration partially result from the hydrophilic nature of M6G because its inflow into the brain compartment was at least 10-fold lower than that of morphine, whereas the rate of elimination of the parent molecule was 3 times greater. After chronic treatment, mice readily develop tolerance and marked physical dependence to the antinociceptive effects of M6G. In vivo binding studies showed that M6G exerts its antinociceptive effect at low (less than 1%) fractional occupancy of [3H]diprenorphine-specific binding sites. In contrast, morphine needs to occupy 9.5 (writhing) to 47 (tail-flick) times more opioid binding sites to produce the same antinociceptive activity. M6G thus appears to have greater pharmacological potency than morphine, which in comparison possesses a low intrinsic efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0022-3565(25)10743-x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 163

Metadata

Authors
Frances, B., Gout, R., Monsarrat, B., Cros, J., & Zajac, J. M.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
1992-07
Volume
262
Issue
1
Pages
25-31
ISSN
0022-3565 (ISSN-L)
OpenAlex
W1831470967
Cited by
163
References
0
FWCI
6.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. https://app.cochat.ai/papers/10.1016/s0022-3565(25)10743-x
The paper
Frances, B., Gout, R., Monsarrat, B., Cros, J., & Zajac, J. M. (1992). Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(25)10743-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.